What question did this study set out to answer?

To assess the incremental cost per quality-adjusted life year (QALY) gained with pan-genotypic sofosbuvir plus velpatasvir compared to current genotype-dependent antiviral regimens in Punjab's universal free treatment scheme.

August 29, 2019PLoS ONEOpen Access

Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India

View Full Paper

Ask AI

Bookmark

Authors

YCYashika ChughPost Graduate Institute of Medical Education and Research RDRadha K. DhimanSanjay Gandhi Post Graduate Institute of Medical Sciences MPMadhumita PremkumarPost Graduate Institute of Medical Education and Research

Discussion

Member takes

Implication

Economic modeling reveals that pan-genotypic sofosbuvir-velpatasvir improves outcomes and reduces costs in hepatitis C, highlighting its universal value.

Key Points

To assess the incremental cost per quality-adjusted life year (QALY) gained with pan-genotypic sofosbuvir plus velpatasvir compared to current genotype-dependent antiviral regimens in Punjab's universal free treatment scheme.
Constructed a Markov model simulating hepatitis C natural history over a lifetime horizon from a societal perspective, applying a 3% annual discount rate to costs and health outcomes.
Evaluated three public scheme scenarios (I: current genotype-dependent care, II: sofosbuvir-velpatasvir for cirrhotic cases only, III: universal sofosbuvir-velpatasvir) against a counterfactual without free treatment.
All public treatment scenarios dominated the counterfactual of no free care, producing greater QALYs and lower overall lifetime costs.
Scenario II dominated Scenario I by generating an additional 0.28 QALYs (0.03 to 0.71) and reducing costs by ₹5,946 (₹1,198 to ₹14,174) per person, alongside a 5.5% program budget increase.
Scenario III gained 0.44 QALYs (0.14 to 1.01) per person relative to Scenario I with an average net saving of ₹2,676 (range: saving of ₹14,835 to extra cost of ₹3,456), but required a 60% budget increase.

Cite This Study

Chugh et al. (2019) studied this question.

synapsesocial.com/papers/6a107cd0d478ddac0ffd0a1e https://doi.org/10.1371/journal.pone.0221769

View Full Paper

Ask AI

Bookmark

Implication

Economic modeling reveals that pan-genotypic sofosbuvir-velpatasvir improves outcomes and reduces costs in hepatitis C, highlighting its universal value.

Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider